PTPRC and thromboangiitis obliterans: Notably, we identified potential inhibitory effects of two ligand-receptor pairs, CD22-PTPRC and BTLA-TNFRSF14, which may contribute to the decrease of Bregs and impaired inhibition of inflammation in active TAO.